Aytu BioPharma, Inc. (AYTU) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $2.56. It has a SharesGrow Score of 50/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Valuation: AYTU trades at a trailing Price-to-Earnings (P/E) of -1.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.01.
Financials: revenue is $66M, -10.5%/yr average growth. Net income is $14M (loss), growing at +35.3%/yr. Net profit margin is -20.4% (negative). Gross margin is 69% (+14.9 pp trend).
Balance sheet: total debt is $23M against $19M equity (Debt-to-Equity (D/E) ratio 1.21, moderate). Current ratio is 1.26 (adequate). Debt-to-assets is 18.5%. Total assets: $124M.
Analyst outlook: 5 / 5 analysts rate AYTU as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 50/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
